Mirus Bio

Mirus Bio is a long-established, private biotechnology company specializing in nucleic acid delivery (transfection) technologies. Its product portfolio, including the TransIT, VirusGEN, and AAViator platforms, serves both basic research and the rapidly growing clinical and commercial-scale manufacturing needs for viral vectors in gene therapy. With a strong publication record, extensive patent portfolio, and a shift towards GMP-grade products, the company is strategically positioned as an essential tools and reagents provider for the biopharmaceutical industry.

Proprietary transfection reagent chemistry for nucleic acid delivery. Core platforms include the TransIT-VirusGEN system for viral vector production, the integrated AAViator Production Platform for AAV, and supporting products like the VirusGEN Complex Stabilizer and Rev IT AAV Enhancer. Products are designed for high efficiency, scalability, and are available in GMP grade for therapeutic manufacturing.

Mirus competes in the crowded life science reagents market against giants like Thermo Fisher Scientific, Merck KGaA (MilliporeSigma), and Sartorius (which owns Polyplus, a direct competitor in transfection for viral vector production). Its differentiation lies in its deep specialization in transfection, a strong reputation in research, and a focused portfolio for AAV manufacturing. However, competitors offer broader bundled solutions and have greater commercial scale.